BBIO vs. TEM: BridgeBio Pharma vs. Tempus AI Stock Comparison

Company Profile

BridgeBio Pharma (BBIO) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

BridgeBio Pharma (BBIO) has been public since June 27, 2019, giving it a longer listed trading history, while Tempus AI (TEM) listed on June 14, 2024 and still has a shorter public-market record.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas BridgeBio Pharma (BBIO) is closer to market-like at 0.93 — a noticeable difference in market-sensitivity profile.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BridgeBio Pharma (BBIO) has no ROE value reported for this period; Tempus AI (TEM) reports a negative figure of -37.55%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

Both BridgeBio Pharma (BBIO) at -59.84% and Tempus AI (TEM) at -12.54% report negative net margin values, usually indicating net losses over the period.

Both BridgeBio Pharma (BBIO) at -3.30% and Tempus AI (TEM) at -13.82% report negative operating margin values, usually indicating operating losses over the period.

Profitability Metrics

Growth

Both BridgeBio Pharma (BBIO) at 126.26% and Tempus AI (TEM) at 83.41% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.

Neither BridgeBio Pharma (BBIO) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.

Only one side’s leverage can be read here: Tempus AI (TEM) carries debt-to-equity ratio of 2.86 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither BridgeBio Pharma (BBIO) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BridgeBio Pharma (BBIO) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither BridgeBio Pharma (BBIO) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Tempus AI (TEM) reports 27.66, ranking against industry peers normally.

Valuation Metrics